Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 453 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Amyotrophic Lateral Sclerosis (ALS) Clear all
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 8, 2026, 1:26 AM EDT
Terminated Phase 1 Interventional

Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

NCT03757351
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
DNL747, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Orlando, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 8, 2026, 1:26 AM EDT
Terminated Phase 2 Interventional Results available

Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)

NCT03679975
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Riluzole Oral Soluble film (ROSF) 50 mg
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 8, 2026, 1:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-Invasive Measurement of Gastrointestinal (GI) Motility in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00714805
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Christine Barr
Other
Eligibility
18 Years to 89 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 8, 2026, 1:26 AM EDT
Withdrawn Phase 2 Interventional

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

NCT00561366
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, Arimoclomol
Drug
Lead sponsor
CytRx
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Pacific Palisades, California • San Francisco, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 8, 2026, 1:26 AM EDT
Completed No phase listed Observational

COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry

NCT04559009
View directory record Official record
Conditions
Covid19, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 8, 2026, 1:26 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

NCT04972487
View directory record Official record
Conditions
Superoxide Dismutase 1-Amyotropic Lateral Sclerosis
Interventions
Tofersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
U.S. locations
19
States / cities
Anchorage, Alaska • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 8, 2026, 1:26 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis

NCT07823101
View directory record Official record
Conditions
IBM, Inclusion Body Myositis, Myopathy, Myositis, ALS (Amyotrophic Lateral Sclerosis), PLS
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 8, 2026, 1:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

NCT01083667
View directory record Official record
Conditions
Familial Amyotrophic Lateral Sclerosis
Interventions
Pyrimethamine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 8, 2026, 1:26 AM EDT
Completed Phase 2 Interventional

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01281631
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
NP001, Placebo
Drug
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
17
States / cities
Scottsdale, Arizona • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 8, 2026, 1:26 AM EDT
Not listed No phase listed Observational

Telespirometry in Amyotrophic Lateral Sclerosis (ALS)

NCT05106569
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Spirometry
Diagnostic Test
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Syracuse, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 8, 2026, 1:26 AM EDT
Recruiting Not applicable Interventional

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)

NCT06094205
View directory record Official record
Conditions
Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked-in Syndrome, Muscular Dystrophies
Interventions
BrainGate Neural Interface System
Device
Lead sponsor
Leigh R. Hochberg, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 8, 2026, 1:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cervical Electrical Stimulation for ALS

NCT03411863
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CES at rest, CES plus active hand or wrist movements
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 8, 2026, 1:26 AM EDT
Completed No phase listed Observational

The E-health Application To Modify ORal Energy Intake and Measure Outcomes REmotely in ALS Clinical Trial (EAT MORE2)

NCT04051333
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ALS Nutrition App (MyDataHelps platform)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 8, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available

Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT01232738
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
rasagiline
Drug
Lead sponsor
Yunxia Wang, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 8, 2026, 1:26 AM EDT
Completed Early Phase 1 Interventional

Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis

NCT03793868
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Perampanel, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 8, 2026, 1:26 AM EDT
Terminated Not applicable Interventional

Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis

NCT02058732
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
MRI
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 8, 2026, 1:26 AM EDT
Terminated Phase 2 Interventional Results available

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03580616
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
L-Serine
Drug
Lead sponsor
Elijah W. Stommel
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 8, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)

NCT01536249
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Cimetidine plus Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 8, 2026, 1:26 AM EDT
Completed No phase listed Observational

Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)

NCT05276349
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Phoenix, Arizona • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 8, 2026, 1:26 AM EDT
No Longer Available No phase listed Expanded access

A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)

NCT06069934
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine
Drug
Lead sponsor
Prilenia
Industry
Eligibility
18 Years and older
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 8, 2026, 1:26 AM EDT
No Longer Available No phase listed Expanded access

Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis

NCT04514952
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 8, 2026, 1:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Olfactory Deficits in Neurologic Disease

NCT05019014
View directory record Official record
Conditions
Alzheimer Disease, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Lewy Body Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 8, 2026, 1:26 AM EDT
Terminated No phase listed Observational

Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient

NCT00718016
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 8, 2026, 1:26 AM EDT